Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs Heron Therapeutics Inc — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.4 (market cap $370.88M), while Heron Therapeutics Inc trades at $0.36 (market cap $68.01M). The key difference: YieldMax COIN Option Income Strategy ETF is far larger — about 5.5× Heron Therapeutics Inc's market cap, and YieldMax COIN Option Income Strategy ETF is more actively traded (595,904 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold YieldMax COIN Option Income Strategy ETF for 41 Days and Heron Therapeutics Inc for 35 Days on average.
| CONY | HRTX | |
|---|---|---|
Market Cap | $370.88M | $68.01M |
Volume | 595,904 | 1,891,941 |
Sector | Income / Options Overlay | Health |
52-Week High | $76.50 | $1.49 |
52-Week Low | $17.73 | $0.27 |
Typical Hold Time | 41 Days | 35 Days |
Enterprise Value | — | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $19.16, down 3.38% today, with a bearish technical outlook as moving averages signal selling pressure. The ETF maintains weekly dividend distributions but faces structural NAV erosion concerns. Recent news highlights regulatory uncertainty impacting crypto-related stocks after Senate cryptocurrency legislation failed to advance.
The outlook remains challenging with significant YTD price decline and ongoing NAV decay despite high distribution rates. Investment opportunity exists for income-focused investors seeking weekly dividends, but structural risks and crypto market volatility present substantial downside exposure.
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
